Cargando…

A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report

Neoadjuvant chemotherapy followed by radical cystectomy is the standard of care for patients diagnosed with muscle-invasive bladder cancer (MIBC). However, urinary diversion following radical cystectomy significantly reduces patient quality of life. In addition, patients who significantly respond to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Chuanzhen, Fu, Zhichao, Liu, Yueping, Zhou, Aiping, Wang, Jianfei, Shou, Jianzhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222973/ https://www.ncbi.nlm.nih.gov/pubmed/34177933 http://dx.doi.org/10.3389/fimmu.2021.684879

Ejemplares similares

Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study
por: Shi, Hongzhe, et al.
Publicado: (2021)

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
por: Liu, David, et al.
Publicado: (2017)

Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer
por: Liu, Ning, et al.
Publicado: (2022)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Bladder Preservation for Muscle Invasive Bladder Cancer
por: Mirza, Arafat, et al.
Publicado: (2016)

Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases
por: Mao, Jiaquan, et al.
Publicado: (2022)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

CYR61 as a potential biomarker for the preoperative identification of muscle-invasive bladder cancers
por: Chen, Huang, et al.
Publicado: (2021)

Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
por: Yang, Zhao, et al.
Publicado: (2021)

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer
por: Rose, Tracy L., et al.
Publicado: (2016)

Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?
por: Smelser, Woodson Wade, et al.
Publicado: (2017)

Bladder preservation in muscle-invasive bladder cancer: a comprehensive review
por: Hamad, Judy, et al.
Publicado: (2020)

Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy
por: Shang, Bingqing, et al.
Publicado: (2022)

Bladder Preservation with Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for the Treatment of Muscle-invasive Carcinoma of the Bladder: A Single-Center Experience
por: Agrawal, Chinmayee, et al.
Publicado: (2020)

Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder
por: Michaelson, M D, et al.
Publicado: (2004)

The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer
por: Wan, Song, et al.
Publicado: (2021)

Perioperative immunotherapy for muscle-invasive bladder cancer
por: Kim, In-Ho, et al.
Publicado: (2020)

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
por: Peyrottes, Arthur, et al.
Publicado: (2021)

Perioperative immunotherapy in muscle-invasive bladder cancer
por: Lee, Hyung Ho, et al.
Publicado: (2020)

Single Institutional Experience of Bladder-Preserving Trimodality Treatment for Muscle-Invasive Bladder Cancer
por: Joung, Jae Young, et al.
Publicado: (2008)

Editorial comment: bladder preservation as a treatment strategy in muscle-invasive bladder cancer
por: Ajib, Khaled, et al.
Publicado: (2018)

The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer
por: Zhiyu, Zhang, et al.
Publicado: (2021)

EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients
por: Zhu, Gongmin, et al.
Publicado: (2020)

Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies
por: Voutsadakis, Ioannis A.
Publicado: (2022)

Exploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden Analysis
por: Ma, Yao, et al.
Publicado: (2019)

Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer
por: Lv, Jia, et al.
Publicado: (2020)

Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy
por: Yang, Zhao, et al.
Publicado: (2018)

A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer
por: Portner, R., et al.
Publicado: (2021)

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes
por: Chen, Zihao, et al.
Publicado: (2021)

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder
por: Hafeez, S, et al.
Publicado: (2015)

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder
por: Hafeez, S, et al.
Publicado: (2016)

Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience
por: Gerardi, Marianna A., et al.
Publicado: (2016)

Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
por: Koga, Fumitaka, et al.
Publicado: (2018)

Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review
por: Fukushima, Hiroshi, et al.
Publicado: (2022)

Somatic mutation of PTEN in bladder carcinoma
por: Aveyard, J S, et al.
Publicado: (1999)

Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden
por: Cazier, J.-B., et al.
Publicado: (2014)

Immunotherapy for bladder cancer
por: Fuge, Oliver, et al.
Publicado: (2015)

Mutational and non mutational adaptation of Salmonella enterica to the gall bladder
por: Urdaneta, Verónica, et al.
Publicado: (2019)

Somatic Mutation of the Non-Muscle-Invasive Bladder Cancer Associated with Early Recurrence
por: Yu, Seong Hyeon, et al.
Publicado: (2023)

Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients
por: Liu, Chunnan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ua52ftbv9cvin3rfnctpi301eh